The National Institutes of Health (NIH) ACTIV-3 clinical research has come to Dallas in force as Baylor Scott & White recruited and treated the first patients to lead the way in this large American city. As TrialSite recently reported, ACTIV-3 centers on a neutralizing monoclonal antibody developed by Lilly via discovery technology from a University of British Columbia spinoff called AbCellera. Meanwhile, Austin Regional Clinic was selected by the Pfizer/BioNTech for their Phase 3 clinical trial to test the BNT162 COVID-19 vaccine.
Baylor Scott & White Research Institute
The first two patients in this study were treated at Baylor Scott & White Research Institute, reported local media KXAN. The novel monoclonal antibody therapy called LY-CoV555 is ideal for a patient that has been hospitalized and in the early stages of COVID-19, but yet ill enough for a respirator, reports Dr. Michael Mack, Chairman of Baylor Scott & White Research Institute.
Dr. Mack suggests the investigational treatment will take “several days to determine the impact of the patients’ health.” During the study, these patients will also receive Remdesivir.
Principal Investigator Point of View
Uriel Sebastian Sandkovsky, MD, MS, principal investigator and an infectious disease physician on staff at Baylor University Medical Center, reports, “Adaptive clinical trials like this one which use a single platform to test multiple promising therapies quickly are examples of the strength that comes from close collaboration between colleagues and scientists across different centers and counties. We are proud to have this trial available at Baylor Scott & White.”
BNT162 Vaccine comes to Texas
In the meantime, the Pfizer/BioNTech BNT162 COVID-19 vaccine trial has come to the Austin Regional Clinic (ARC), which now seeks 250 patients from across central Texas for the late phase Pfizer vaccine originally developed in Germany and known as BNT162.
KXAN reports that Jeff Repper, director of ARC Clinical Research, commented, “This study offers an opportunity to be part of history and benefit humankind. There are 7 billion people in our world who will need access to a vaccine to prevent COVID-19 infection, and ARC Clinical Research is thrilled to have a role in bringing a vaccine to Americans.”
Those enrolling will be paid for their time and contributions to the vaccine trial. All COVID-19 vaccine clinical trial services are delivered to ARC Clinical Research Wilson Parke, located in Austin’s Four Points Neighborhood.
About Austin Regional Clinic
Austin Regional Clinic is a multispecialty group offering patients accessible, reliable, convenient healthcare. Focusing on primary care—family practice, pediatrics, internal medicine—and 21 specialties, the clinic stresses prevention, evidence-based treatment, same-day access, long-term doctor/patient relationships, and coordinated care. They provide high-quality care for all of our patients without regard to race, color, religion, sex, gender identity, gender expression, national origin, age, disabilities, sexual orientation, genetics, veteran status or any other basis. Founded as an association in 1980, today ARC is one of central Texas’ largest professional medical groups.
ARC Clinical Research
The Clinical Research institute includes several locations and involves a number of therapeutic and focus areas. Cara Kunkel, a nurse working for ARC, sees the impact of COVID-19 on this Central Texas community. She reported, “I feel for the patients who are dealing not only with chronic health problems, but some of them are becoming COVID positive and actually fighting for their lives,” she emphasized. The ARC research team is looking for participants who are 18 years of age or older and who have high-risk exposure to COVID-19.
About Baylor Scott & White Research Institute
Baylor Scott & White Research Institute is the dedicated research and development arm of the largest not-for-profit healthcare system in Texas. BSWRI provides the critical infrastructure and operational resources needed to both safely and effectively conduct research across a broad range of specialty areas, including cancer and heart and vascular.